• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Outcomes, Registries and Medical Marijuana: Towards Establishing Dispensary Monitoring and Reporting Standards.结果、登记处与医用大麻:迈向建立药房监测与报告标准
Innov Pharm. 2018 Nov 30;9(4). doi: 10.24926/iip.v9i4.1527. eCollection 2018.
2
Establishing Credibility for Medical Marijuana: The Proposed Prometheus Dispensary Registry for Botanical Cannabis.确立医用大麻的可信度:拟议的植物大麻普罗米修斯药房注册制度。
Innov Pharm. 2019 Aug 31;10(1). doi: 10.24926/iip.v10i1.1553. eCollection 2019.
3
Tracking and Reporting Outcomes in Medical Marijuana: Establishing Condition Specific State Level Registries.医用大麻的结果跟踪与报告:建立特定病情的州级登记系统。
Innov Pharm. 2019 Aug 31;10(2). doi: 10.24926/iip.v10i2.1800. eCollection 2019.
4
Establishing Practice Risk Management and Outcomes Claims for Medical Marijuana Dispensaries: Questions Legislators Should Ask.为医用大麻药房建立实践风险管理和结果声明:立法者应提出的问题
Innov Pharm. 2019 Aug 31;10(1). doi: 10.24926/iip.v10i1.1596. eCollection 2019.
5
Validation of secondary data sources for enumerating marijuana dispensaries in a state commercializing marijuana.验证在一个将大麻商业化的州中用于计数大麻药房的二级数据源。
Drug Alcohol Depend. 2020 Oct 1;215:108183. doi: 10.1016/j.drugalcdep.2020.108183. Epub 2020 Aug 2.
6
State licenses for medical marijuana dispensaries: neighborhood-level determinants of applicant quality in Missouri.医用大麻药房的州许可证:密苏里州申请人资质的邻里层面决定因素
J Cannabis Res. 2024 Mar 26;6(1):17. doi: 10.1186/s42238-024-00223-1.
7
Examination of Market Segmentation among Medical Marijuana Dispensaries.医用大麻药房的市场细分研究
Subst Use Misuse. 2018 Jul 29;53(9):1463-1467. doi: 10.1080/10826084.2017.1413391. Epub 2018 Jan 5.
8
Marijuana Promotion Online: an Investigation of Dispensary Practices.网上大麻推销:对药房做法的调查。
Prev Sci. 2019 Feb;20(2):280-290. doi: 10.1007/s11121-018-0889-2.
9
Association of State Policies Allowing Medical Cannabis for Opioid Use Disorder With Dispensary Marketing for This Indication.州政策允许将医用大麻用于阿片类药物使用障碍与该适应症的药房营销之间的关联。
JAMA Netw Open. 2020 Jul 1;3(7):e2010001. doi: 10.1001/jamanetworkopen.2020.10001.
10
Barriers to Achieving Optimal Success with Medical Cannabis: Opportunities for Quality Improvement.实现医用大麻最佳疗效的障碍:质量改进的机遇。
J Altern Complement Med. 2019 Jan;25(1):5-7. doi: 10.1089/acm.2018.0250. Epub 2018 Sep 6.

引用本文的文献

1
The Imaginary Worlds of Cure Proportion Modeling: Survivorship and Reference Case Pricing of Transformative Therapies.治愈比例建模的虚构世界:变革性疗法的生存率及参考案例定价
Innov Pharm. 2019 Oct 3;10(3). doi: 10.24926/iip.v10i3.2241. eCollection 2019.
2
Tracking and Reporting Outcomes in Medical Marijuana: Establishing Condition Specific State Level Registries.医用大麻的结果跟踪与报告:建立特定病情的州级登记系统。
Innov Pharm. 2019 Aug 31;10(2). doi: 10.24926/iip.v10i2.1800. eCollection 2019.
3
A Practice Based Behavioral Health Management Registry (BHMR): Implementation, Structure and Content.基于实践的行为健康管理注册库(BHMR):实施、结构与内容
Innov Pharm. 2019 Aug 31;10(2). doi: 10.24926/iip.v10i2.1782. eCollection 2019.
4
A Practice Based Chronic Pain Management Registry (CPMR): Structure and Content of Proposed Patient and Patient/Provider Platforms.基于实践的慢性疼痛管理登记系统(CPMR):拟议的患者及患者/提供者平台的结构与内容
Innov Pharm. 2019 Aug 31;10(1). doi: 10.24926/iip.v10i1.1628. eCollection 2019.
5
Establishing Practice Risk Management and Outcomes Claims for Medical Marijuana Dispensaries: Questions Legislators Should Ask.为医用大麻药房建立实践风险管理和结果声明:立法者应提出的问题
Innov Pharm. 2019 Aug 31;10(1). doi: 10.24926/iip.v10i1.1596. eCollection 2019.
6
Establishing Credibility for Medical Marijuana: The Proposed Prometheus Dispensary Registry for Botanical Cannabis.确立医用大麻的可信度:拟议的植物大麻普罗米修斯药房注册制度。
Innov Pharm. 2019 Aug 31;10(1). doi: 10.24926/iip.v10i1.1553. eCollection 2019.

本文引用的文献

1
Patient-Reported Symptom Relief Following Medical Cannabis Consumption.医用大麻消费后患者报告的症状缓解情况。
Front Pharmacol. 2018 Aug 28;9:916. doi: 10.3389/fphar.2018.00916. eCollection 2018.
2
Preliminary evaluation of the efficacy, safety, and costs associated with the treatment of chronic pain with medical cannabis.医用大麻治疗慢性疼痛的疗效、安全性及成本的初步评估。
Ment Health Clin. 2018 Apr 26;8(3):110-115. doi: 10.9740/mhc.2018.05.110. eCollection 2018 May.
3
The Association Between Cannabis Use and Aberrant Behaviors During Chronic Opioid Therapy for Chronic Pain.慢性疼痛患者接受阿片类药物慢性治疗期间大麻使用与异常行为的关联。
Pain Med. 2018 Oct 1;19(10):1997-2008. doi: 10.1093/pm/pnx222.
4
The grass is not always greener: a multi-institutional pilot study of marijuana use and acute pain management following traumatic injury.并非总是别人家的草更绿:一项关于创伤性损伤后使用大麻与急性疼痛管理的多机构试点研究。
Patient Saf Surg. 2018 Jun 19;12:16. doi: 10.1186/s13037-018-0163-3. eCollection 2018.
5
Medical Cannabis for Neuropathic Pain.医用大麻治疗神经性疼痛。
Curr Pain Headache Rep. 2018 Feb 1;22(1):8. doi: 10.1007/s11916-018-0658-8.
6
Medical use of cannabis and cannabinoids containing products - Regulations in Europe and North America.医用大麻及含大麻素产品的使用 - 欧洲和北美的法规。
Eur J Intern Med. 2018 Mar;49:2-6. doi: 10.1016/j.ejim.2018.01.001. Epub 2018 Jan 10.
7
Practical considerations in medical cannabis administration and dosing.医疗大麻给药和剂量方面的实际考虑因素。
Eur J Intern Med. 2018 Mar;49:12-19. doi: 10.1016/j.ejim.2018.01.004. Epub 2018 Jan 4.
8
Training and Practices of Cannabis Dispensary Staff.大麻药房工作人员的培训与实践
Cannabis Cannabinoid Res. 2016 Dec 1;1(1):244-251. doi: 10.1089/can.2016.0024. eCollection 2016.
9
Marijuana Use in the Elderly: Implications and Considerations.老年人使用大麻:影响与考量
Consult Pharm. 2017 Jun 1;32(6):341-351. doi: 10.4140/TCP.n.2017.341.
10
CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016.美国 2016 年慢性疼痛阿片类药物处方指南。
MMWR Recomm Rep. 2016 Mar 18;65(1):1-49. doi: 10.15585/mmwr.rr6501e1.

结果、登记处与医用大麻:迈向建立药房监测与报告标准

Outcomes, Registries and Medical Marijuana: Towards Establishing Dispensary Monitoring and Reporting Standards.

作者信息

Langley Paul C

机构信息

Adjunct Professor, College of Pharmacy, University of Minnesota.

出版信息

Innov Pharm. 2018 Nov 30;9(4). doi: 10.24926/iip.v9i4.1527. eCollection 2018.

DOI:10.24926/iip.v9i4.1527
PMID:34007733
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7640779/
Abstract

The acceptance by a large number of state governments of medical marijuana dispensaries and the regulatory framework to support their licensing has put to one side the issue of monitoring and reporting outcomes. This is a major oversight. It is an untenable situation given the limited evidence base for the clinical benefits and risks associated with dispensed botanical marijuana. The purpose of this commentary is to propose that, as a condition of licensing, marijuana dispensaries should be required to establish a registry to support ongoing monitoring of patient response associated with botanical cannabis formulations. Patients should be monitored over the course of their treatment to assess, in the case of severe non-cancer pain as an example, pain intensity and functional status by pain location. The dispensary, in meeting required audit standards, should be in a position to report on patient response over baseline to the provider who has recommended botanical cannabis. As well, registries should be in a position to report to state licensing agencies response to therapy by target patient groups. Establishing site-specific registries should go some way to meeting the present evidence deficit for botanical marijuana, reducing barriers to its acceptance by providers, patients and health agencies.

摘要

许多州政府对医用大麻药房的认可以及支持其许可的监管框架,将监测和报告结果的问题搁置在了一边。这是一个重大疏忽。鉴于与分发的植物性大麻相关的临床益处和风险的证据基础有限,这种情况是站不住脚的。本评论的目的是提议,作为许可条件,应要求大麻药房建立一个登记系统,以支持对与植物性大麻制剂相关的患者反应进行持续监测。应以重度非癌性疼痛为例,在患者治疗过程中对其进行监测,以按疼痛部位评估疼痛强度和功能状态。药房在符合所需的审计标准时,应能够向推荐植物性大麻的医疗服务提供者报告患者相对于基线的反应情况。此外,登记系统应能够向州许可机构报告目标患者群体对治疗的反应。建立特定地点的登记系统应在一定程度上弥补目前植物性大麻的证据不足,减少医疗服务提供者、患者和卫生机构接受它的障碍。